Semaglutide vs Tirzepatide vs Retatrutide: Single, Dual, and Triple Agonist Compared

Semaglutide targets one receptor. Tirzepatide targets two. Retatrutide targets three. This is not just a marketing escalation — each additional receptor target changes the pharmacology in meaningful ways, and the clinical data reflects that. This comparison covers the three most significant incretin-based medications, what their mechanism differences actually mean, and where the evidence stands for each.

Quick Reference: Single vs Dual vs Triple Agonist

• Semaglutide (Ozempic/Wegovy): GLP-1 only. FDA-approved. 14.9% average weight loss (STEP 1).
• Tirzepatide (Mounjaro/Zepbound): GLP-1 + GIP. FDA-approved. 22.5% average weight loss (SURMOUNT-1).
• Retatrutide (investigational): GLP-1 + GIP + glucagon. Not yet approved. 24.2% Phase 2 / ~28.7% Phase 3 weight loss.
• Each additional receptor target adds a distinct metabolic lever — not just "more of the same."
• Retatrutide cannot be prescribed or purchased outside of clinical trials.

Comparison Table

How the Mechanisms Differ

Semaglutide: The Single Agonist

Semaglutide activates GLP-1 receptors only. This single pathway delivers:

• Appetite suppression via hypothalamic signaling
• Delayed gastric emptying (you feel full longer)
• Enhanced glucose-dependent insulin secretion
• Reduced hepatic glucose output
• Modest effects on food reward pathways in the brain

The GLP-1 pathway is the foundation of modern incretin therapy. Semaglutide proved that sustained, potent GLP-1 receptor activation alone can produce clinically meaningful weight loss — something earlier, less potent GLP-1 agonists like liraglutide achieved only modestly.

Tirzepatide: The Dual Agonist

Tirzepatide adds GIP receptor activation to the GLP-1 foundation. GIP (glucose-dependent insulinotropic polypeptide) does several things that GLP-1 does not:

• Enhances insulin sensitivity in peripheral tissues (muscle, fat)
• Influences lipid metabolism and fat storage patterns
• May increase energy expenditure through effects on adipose tissue
• Amplifies GLP-1's appetite-suppressing effects through complementary pathways

The result, clinically, is a jump from ~15% to ~22% average body weight loss. That is not a marginal improvement — it represents a different tier of efficacy.

A key detail: tirzepatide's molecular backbone is based on the GIP peptide. It has approximately five-fold stronger affinity for GIP receptors than GLP-1 receptors. This means calling it a "GLP-1 medication" is technically accurate but undersells the GIP contribution.

Retatrutide: The Triple Agonist

Retatrutide adds a third target — the glucagon receptor — to the GLP-1/GIP base. Glucagon is conventionally thought of as a counter-regulatory hormone (it raises blood sugar), which makes agonizing its receptor seem counterintuitive in a diabetes/obesity context. Here's why it works:

Energy expenditure: Glucagon receptor activation increases thermogenesis and resting energy expenditure. While GLP-1 and GIP primarily work on the input side (appetite, nutrient absorption), glucagon works on the output side (how many calories you burn at rest).

Lipolysis: Glucagon promotes fat breakdown in hepatic and adipose tissue. In the Phase 2a MASLD trial, retatrutide reduced liver fat by an average of 37%, with complete resolution of steatosis in a significant proportion of participants.

Hepatic glucose effects: Glucagon does raise hepatic glucose output, but in retatrutide's formulation, the GLP-1 and GIP components counterbalance this effect. Phase 2 data in type 2 diabetes showed A1C reductions of up to 2.16%, confirming that the net glycemic effect is still beneficial.

The triple mechanism creates a metabolic profile that no previous medication has achieved: appetite suppression (GLP-1), peripheral insulin sensitization and fat metabolism (GIP), plus increased energy expenditure and hepatic fat mobilization (glucagon).

Clinical Trial Results

STEP Program (Semaglutide)

The STEP trials established semaglutide 2.4 mg as the weight management standard.

• STEP 1 (N=1,961, non-diabetic, 68 weeks): -14.9% body weight vs -2.4% placebo. 32% of participants achieved >20% weight loss.
• STEP 2 (N=1,210, type 2 diabetes, 68 weeks): -9.6% body weight (lower in diabetic populations, as expected).
• STEP 3 (with intensive behavioral therapy): -16.0% body weight.
• STEP 4 (withdrawal study): Participants who stopped semaglutide regained ~2/3 of lost weight over 48 weeks.

The SELECT trial added cardiovascular outcome data: 20% reduction in major adverse CV events in adults with obesity and established CV disease.

SURMOUNT Program (Tirzepatide)

• SURMOUNT-1 (N=2,539, non-diabetic, 72 weeks): -16.0% at 5 mg, -21.4% at 10 mg, -22.5% at 15 mg. 63% of 15 mg participants lost >20%. Placebo: -3.1%.
• SURMOUNT-2 (N=938, type 2 diabetes, 72 weeks): -14.7% at 15 mg (larger effect in diabetic patients compared to semaglutide's diabetes cohort).
• SURMOUNT-3 (with intensive lifestyle intervention): -26.6% at maximum dose.
• SURMOUNT-4 (withdrawal study): Weight regain patterns similar to STEP 4.

Retatrutide Phase 2 and Phase 3 Data

Phase 2 (N=338, non-diabetic, 48 weeks, published NEJM 2023):

• 1 mg: -8.7%
• 4 mg: -17.1%
• 8 mg: -22.8%
• 12 mg: -24.2%
• Placebo: -2.1%
• Notably, the weight loss curve at 48 weeks had not plateaued at the highest dose — suggesting even greater loss with longer treatment.

Phase 2 in Type 2 Diabetes (published in The Lancet, 2023):

• A1C reduction up to -2.16% at 12 mg over 36 weeks
• Weight loss up to -16.94% (over a shorter duration than the obesity trial)

Phase 3 TRIUMPH-3 (Eli Lilly press release, 2025):

• 68-week data in obesity: average weight loss of approximately 28.7% (~71.2 lbs) at the highest dose
• 93% achieved >10% weight loss; 76% achieved >20%
• Full peer-reviewed publication pending

The Phase 3 numbers are remarkable. If they hold up in the full publications and FDA review, retatrutide would represent the most effective pharmaceutical weight-loss treatment ever studied.

Liver Fat Data

Retatrutide's glucagon component gives it a distinct advantage in metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD). In the Phase 2a MASLD trial:

• Average relative liver fat reduction: -37% at 48 weeks
• Complete resolution of hepatic steatosis in a significant subset of participants
• These effects exceeded what has been observed with semaglutide or tirzepatide, likely due to glucagon's direct hepatic lipolytic activity

Dosing Comparison

*Phase 2 dosing schedule. Final approved titration may differ.

All three are once-weekly injections. All use SubQ administration (abdomen, thigh, or upper arm). The practical injection experience is likely to be similar across all three.

Side Effects Comparison

The GI side effect profile is broadly consistent across all three medications, which makes sense — all activate GLP-1 receptors, and GLP-1 activation is the primary driver of nausea and GI symptoms.

Nausea: Semaglutide ~44% (STEP 1, likely inflated by faster titration), tirzepatide 24-33%, retatrutide ~26% at 12 mg in Phase 2. The generally lower rates with tirzepatide and retatrutide may reflect more gradual titration protocols or GIP-mediated modulation of nausea pathways.

Diarrhea: Semaglutide ~30%, tirzepatide 18-25%, retatrutide ~22% at 12 mg. Broadly comparable.

Vomiting: Semaglutide ~24%, tirzepatide 9-13%, retatrutide ~14% at 12 mg.

Decreased appetite: Common with all three and is, in a sense, the desired pharmacological effect. Reported as an adverse event in 20-30% across trials.

Retatrutide-specific signals: The Phase 2 trial did not reveal major new safety signals compared to tirzepatide. Theoretical concerns about glucagon-mediated hyperglycemia have not materialized in the trial data so far. Phase 3 data noted dysesthesia (altered sense of touch) as a new signal worth monitoring.

Discontinuation rates due to side effects: Roughly 5-7% across all three medications, suggesting that while GI symptoms are common, they are manageable for most patients.

Long-term safety data favors semaglutide (years of post-market data) > tirzepatide (growing post-market data) > retatrutide (clinical trial data only). This is a practical consideration that matters.

Practical Tracking Considerations

If you are currently on semaglutide or tirzepatide, or planning to transition to retatrutide when it becomes available, tracking matters for all the same reasons — and a few additional ones.

For patients on any of these medications:

• Log every injection: date, time, dose, site
• Track weight weekly under consistent conditions
• Monitor GI symptoms, especially during titration
• Record missed doses and how they were handled
• Bring tracked data to every prescriber appointment

If you're transitioning between agents:

• Your body will be adapting to different receptor activation profiles
• Side effect patterns may change even at "equivalent" doses — there's no direct dose equivalence between these drugs
• Weight trajectory may shift during the transition
• Document everything during the switch so your prescriber has real data to work with

For patients interested in retatrutide:

• Clinical trial enrollment is the only current path to access
• If you do enroll, trial protocols will have their own tracking requirements
• Maintain your personal tracking in parallel — trial data belongs to the trial, your personal log belongs to you

Which Fits Your Situation

Semaglutide is right if:

• You need a proven, FDA-approved treatment with years of safety data
• Cardiovascular risk reduction is a priority (SELECT trial data)
• Your insurance covers Wegovy/Ozempic and you're responding well
• An oral option is appealing (Rybelsus, though less effective — see our Rybelsus vs Ozempic comparison)

Tirzepatide is right if:

• You want maximum currently-available weight loss
• You prefer flexible maintenance dosing (5/10/15 mg)
• You've plateaued on semaglutide
• Type 2 diabetes management is a concurrent goal (strong A1C data)

Retatrutide may be right if (once available):

• You have significant obesity with metabolic complications including fatty liver disease
• Previous GLP-1 or dual agonist therapy was insufficient
• You are willing to use a newer medication with less long-term safety data
• Your prescriber recommends it based on your clinical profile

The trajectory of this drug class is clear: each generation targets more pathways and produces more weight loss. But more is not automatically better for every patient. Proven safety, insurance access, and tolerability matter just as much as peak efficacy numbers.

Frequently Asked Questions

Which causes the most weight loss: semaglutide, tirzepatide, or retatrutide?

Based on available trial data, retatrutide has produced the highest average weight loss — up to 24.2% in Phase 2 and approximately 28.7% in Phase 3 at the highest dose. Tirzepatide follows at 22.5% (SURMOUNT-1, 15 mg), and semaglutide at 14.9% (STEP 1, 2.4 mg). However, retatrutide is still investigational and not yet FDA-approved.

When will retatrutide be available?

Eli Lilly's Phase 3 TRIUMPH program is expected to complete by late 2026. If the FDA submission and review go smoothly, approval could come by mid-to-late 2027. These timelines are estimates and subject to change.

Can you take retatrutide now?

No. Retatrutide is not FDA-approved and is only available through clinical trial enrollment. It cannot be legally prescribed, compounded, or purchased outside of a research setting.

Is a triple agonist safer or more dangerous than a dual or single agonist?

Phase 2 data for retatrutide shows a GI side effect profile broadly similar to semaglutide and tirzepatide — nausea, diarrhea, vomiting, and decreased appetite. The addition of glucagon receptor agonism raised theoretical concerns about blood glucose increases, but trial data has not shown clinically meaningful hyperglycemia. Full Phase 3 safety data is still pending.

What does the glucagon receptor add in retatrutide?

Glucagon receptor activation increases hepatic glucose output (which incretin activity counterbalances), boosts energy expenditure, promotes lipolysis (fat breakdown), and may reduce liver fat. The net effect in retatrutide is additive weight loss beyond what GLP-1/GIP dual agonism achieves alone.

Sources

1. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
2. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038
3. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972
4. Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes. Lancet. 2023;402(10401):529-544. doi:10.1016/S0140-6736(23)01053-X
5. Eli Lilly. Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs in first successful Phase 3 trial. Press release
6. Sanyal AJ, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease. Nat Med. 2024. doi:10.1038/s41591-024-03018-2

Tracking your injectable medication — whether it's a single, dual, or triple agonist — is essential for optimizing your results and giving your prescriber actionable data. DoneDose makes it simple: log injections, monitor side effects, and track your progress over time.